Durability of mepolizumab treatment response between doses Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010
Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – a 5-month study in Canada Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Real-world treatment patterns of mepolizumab therapy in Canada Source: Virtual Congress 2020 – Management of chronic lung conditions Year: 2020
Safety and tolerability of indacaterol over 52 weeks of treatment in COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020 Year: 2021
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis Source: ISSN=ISSN 1810-6838, ISBN=, page=69 Year: 2007
Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Managed adjustable dosing of budesonide/formoterol combination is similarly well tolerated to fixed dosing Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening Source: Eur Respir J 2001; 17: 1083-1088 Year: 2001
Three years follow up after injection omalizumab therapy Source: International Congress 2017 – Asthma management Year: 2017